FDA Approves AVTOZMA — CELLTRION USA, Inc.

On January 21, 2026, the FDA approved AVTOZMA (tocilizumab) for subcutaneous administration, marking an expansion of Celltrion USA, Inc.’s portfolio ahead of potential biosimilar competition. Market implications include increased access to tocilizumab for rheumatoid arthritis and systemic juvenile idiopathic arthritis patients through a more convenient administration route.